SAN
DIEGO, Nov. 7, 2023 /PRNewswire/ -- Heron
Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology
company focused on improving the lives of patients by developing
and commercializing therapeutic innovations that improve medical
care, today announced that the company will host a conference call
and live webcast on Tuesday, November 14,
2023 at 4:30 p.m. ET to report
third quarter 2023 financial results and discuss recent business
highlights.
The conference call can be accessed by dialing (646) 307-1963 in
the U.S. or (800) 715-9871 internationally. Please provide
the operator with the passcode 5940799 to join the conference call.
The conference call will also be available via webcast under the
Investor Relations section of Heron's website at www.herontx.com.
An archive of the teleconference and webcast will also be made
available on Heron's website for 60 days following the call.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology
company focused on improving the lives of patients by developing
best-in-class treatments to address some of the most important
unmet patient needs. Our advanced science, patented technologies,
and innovative approach to drug discovery and development have
allowed us to create and commercialize a portfolio of products that
aim to advance the standard-of-care for acute care and oncology
patients. For more information, visit www.herontx.com.
Forward-looking Statements
This news release contains "forward-looking statements" as
defined by the Private Securities Litigation Reform Act of 1995.
Heron cautions readers that forward-looking statements are based on
management's expectations and assumptions as of the date of this
news release and are subject to certain risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, but are not limited to, risks and
uncertainties identified in the company's filings with
the Securities and Exchange Commission. Forward-looking
statements reflect our analysis only on their stated date, and
Heron takes no obligation to update or revise these statements
except as may be required by law.
Investor Relations and Media Contact:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
iduarte@herontx.com
858-251-4400
View original content to download
multimedia:https://www.prnewswire.com/news-releases/heron-therapeutics-to-report-third-quarter-2023-financial-results-on-tuesday-november-14-2023-301980618.html
SOURCE Heron Therapeutics, Inc.